Product
300mg Netupitant + 0.5mg Palonosetron Hydrochloride
1 clinical trial
1 indication
Indication
Chemotherapy-Induced Nausea and VomitingClinical trial
A Phase IV, Real World Observational Study On The Use Of Akynzeo® (Netupitant/Palonosetron) For The Prevention Of Nausea and Vomiting in Oncology Patients Receiving Highly Emetogenic Chemotherapy (HEC) Over Multiple Cycles.Status: Completed, Estimated PCD: 2019-12-30